Core Insights - Three companies, Evommune, BillionToOne, and Grupo Aeroméxico, went public on November 6, raising a total of $646 million, averaging approximately $215 million per company [1] Group 1: Evommune (EVMN) - Evommune opened at $17.25, a 7.25% increase from the offering price, and closed at $20.23, marking a 26.44% rise with a total market capitalization of $608 million [2][5] - The company issued 9.38 million shares at an offering price of $16, raising $150 million [5] - Evommune focuses on innovative therapies for immune-mediated inflammatory mechanisms, projecting $3 million in revenue and a net loss of $28.12 million for the first half of 2025 [5] Group 2: BillionToOne (BLLN) - BillionToOne opened at $100, a 66.67% increase from the offering price, and closed at $108.94, reflecting an 81.57% gain with a total market capitalization of $4.795 billion [6][9] - The company issued 4.55 million shares at an offering price of $60, raising $273 million [9] - BillionToOne specializes in molecular diagnostics, developing prenatal and oncology diagnostic products through its single-molecule next-generation sequencing (smNGS) platform, with projected revenue of $126 million and a net loss of $4.23 million for the first half of 2025 [9] Group 3: Grupo Aeroméxico (AERO) - Grupo Aeroméxico opened at $19.16, a slight increase of 0.84%, and closed at $20.35, resulting in a 7.11% rise with a total market capitalization of $2.969 billion [9][11] - The company issued 11.73 million shares at an offering price of $19, raising $223 million [11] - Grupo Aeroméxico provides domestic and international flight services, covering 22 countries and 52 international cities, with projected revenue of $2.498 billion and a net profit of $89.97 million for the first half of 2025 [11]

Core Viewpoint - Evommune (EVMN.US) has successfully entered the US stock market, experiencing a price increase of over 15%, currently trading at $18.38, with an IPO price set at $16 [1] Company Overview - Evommune is a clinical-stage biopharmaceutical company focused on developing innovative therapies for the treatment of immune-mediated chronic inflammatory diseases [1] - The diseases targeted by Evommune include chronic urticaria, atopic dermatitis, and other conditions related to mast cells and inflammation [1]

Core Viewpoint - Evommune (EVMN.US) has successfully launched on the US stock market, with its stock price increasing over 15% to $18.38, compared to its IPO price of $16 [1] Company Overview - Evommune is a clinical-stage biopharmaceutical company focused on developing innovative therapies for the treatment of immune-mediated chronic inflammatory diseases [1] - The diseases targeted by Evommune include chronic urticaria, atopic dermatitis, and other conditions related to mast cells and inflammation [1]

Core Points - Evommune, Inc. has priced its initial public offering (IPO) at $16.00 per share, offering 9,375,000 shares, with expected gross proceeds of $150 million [1][2] - The shares are set to begin trading on the New York Stock Exchange under the symbol "EVMN" on November 6, 2025, with the offering expected to close on November 7, 2025 [2] - The company is focused on developing innovative therapies targeting chronic inflammatory diseases, aiming to improve patients' daily lives and address the limitations of existing therapies [5] Company Overview - Evommune, Inc. is a clinical-stage biotechnology company dedicated to creating therapies that address key drivers of chronic inflammatory diseases [5] - The company's mission includes preventing long-term effects of uncontrolled inflammation through a portfolio of differentiated product candidates [5] Offering Details - The IPO includes a 30-day option for underwriters to purchase an additional 1,406,250 shares at the initial offering price [1] - Joint book-running managers for the offering include Morgan Stanley, Leerink Partners, Evercore ISI, and Cantor [2]

Core Insights - Eight new stocks were listed last week, including one direct listing company, raising significant capital across various sectors [1][2][3]. Group 1: Recent IPOs - MapLight Therapeutics (MPLT) raised $251 million by issuing 14.75 million shares at $17 each [1]. - Navan (NAVN) raised $923 million by issuing 36.92 million shares at $25 each [1]. - Boyd Group Services (BGSI) raised $780 million by issuing 5.5 million shares at $141 each [2]. - Nomadar (NOMA) entered Nasdaq through a direct listing [3]. Group 2: Upcoming IPOs - BETA Technologies, Inc. plans to list on NYSE with a target date of November 4, 2025, aiming to raise approximately $825 million by issuing 25 million shares at $27 to $33 each. The company reported revenue of $15.57 million in the first half of 2025, up from $7.59 million in the same period last year, with a net loss of $159 million [4][6]. - Exzeo Group, Inc. plans to list on NYSE on November 5, 2025, aiming to raise about $176 million by issuing 8 million shares at $20 to $22 each. The company reported revenue of $109 million in the first half of 2025, up from $60.31 million year-over-year, with a net profit of $39.61 million [6][8]. - Evommune, Inc. plans to list on NYSE on November 6, 2025, aiming to raise approximately $159 million by issuing 9.38 million shares at $15 to $17 each. The company reported revenue of $3 million in the first half of 2025, down from $7 million year-over-year, with a net loss of $28.12 million [10]. - Grupo Aeroméxico, S.A.B. de C.V. plans to list on NYSE on November 6, 2025, aiming to raise about $235 million by issuing 11.73 million shares at $18 to $20 each. The company reported revenue of $2.498 billion in the first half of 2025, down from $2.695 billion year-over-year, with a net profit of $89.97 million [12]. - BillionToOne, Inc. plans to list on NASDAQ on November 6, 2025, aiming to raise approximately $212 million by issuing 3.85 million shares at $49 to $55 each. The company reported revenue of $126 million in the first half of 2025, up from $69.09 million year-over-year, with a net loss of $4.23 million [14]. - Off The Hook YS Inc. plans to list on NYSE MKT on November 7, 2025, aiming to raise about $30 million by issuing 5 million shares at $4 to $6 each. The company reported revenue of $58.59 million in the first half of 2025, up from $51.85 million year-over-year, with a net profit of $840,000 [16].

Core Points - Evommune, Inc. has filed a registration statement for an initial public offering (IPO) of its common stock, offering 9,375,000 shares at an expected price between $15.00 and $17.00 per share [1] - The company plans to grant underwriters a 30-day option to purchase an additional 1,406,250 shares in connection with the IPO [1] - Evommune's common stock is expected to be listed on the New York Stock Exchange under the symbol "EVMN" [1] - The registration statement is anticipated to become effective on November 5, 2025, allowing the company to price the offering shortly thereafter [1] - Morgan Stanley, Leerink Partners, Evercore ISI, and Cantor are acting as joint book-running managers for the proposed offering [2] Company Overview - Evommune, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies targeting chronic inflammatory diseases [5] - The company's mission is to enhance patients' daily lives and mitigate long-term effects of uncontrolled inflammation caused by existing therapy limitations [5] - Evommune is advancing a portfolio of differentiated product candidates aimed at addressing key drivers of chronic inflammation [5]

Group 1 - Evommune, a biotech company focused on therapies for chronic inflammatory diseases, announced its IPO terms, aiming to raise $150 million by offering 9.4 million shares at a price range of $15 to $17 [1] - The company's lead candidate, EVO756, is a potent and selective MRGPRX2 oral small molecule antagonist for chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), currently in a Phase 2b trial with results expected in the second half of 2026 [1] - Evommune's second candidate, EV0301, is a long-acting fusion protein for treating atopic dermatitis (AD) and ulcerative colitis (UC), with plans to initiate a Phase 2 trial for moderate to severe UC patients in 2026 [1] Group 2 - Founded in 2020, Evommune reported revenue of $3 million for the 12 months ending June 30, 2025, and plans to list on the New York Stock Exchange under the ticker "EVMN" [2] - The company has appointed Morgan Stanley, Leerink Partners, Evercore ISI, and Cantor Fitzgerald as joint book-running managers for the IPO, with the final pricing expected during the week of November 3, 2025 [2]

Table of Contents Amendment No.1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 EVOMMUNE, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2834 85-0742575 (Primary Standard Industrial Classification Code Number) 1841 Page Mill Road, Suite 100 Palo Alto, CA 94304 Telephone: (925) 247-4487 As filed with the U.S. Securities and Exchange Commission on October 17, 2025. Registration No. 333-290793 UNITED STATE ...

Group 1 - The article discusses the services provided by IPO Edge, which includes actionable information on growth stocks, first-look IPO filings, previews of upcoming IPOs, an IPO calendar, a database of U.S. IPOs, and a comprehensive guide to IPO investing [1]

Core Insights - The U.S. IPO market remains active despite government shutdown, with 6 traditional IPOs and 2 SPACs launched this week, alongside 13 companies filing for initial public offerings [1][12]. Group 1: IPO Activity - Alliance Laundry Holdings (ALH) raised $826 million, pricing at the upper limit of its range, achieving a market cap of $4.5 billion, and saw a 14% stock price increase [1]. - Phoenix Education Partners (PXED) raised $136 million, pricing at the midpoint of its range, with a market cap of $1.3 billion and a 13% stock price increase [1]. - Ping An Good Doctor (POM) raised $20 million, pricing at the lower limit of its range, with a market cap of $474 million and a 9% stock price increase [2]. - One and One Green Tech (YDDL) raised $10 million, pricing at the midpoint of its range, achieving a market cap of $27 million and a significant 31% stock price increase [2]. - Leifras (LFS) raised $5 million, pricing at the lower limit of its range, with a market cap of $10.5 million, but experienced a 5% stock price decline [2]. - Turn Therapeutics (TTRX) debuted via direct listing at $10, but saw a 26% decline in stock price [3]. Group 2: SPAC Activity - Two SPACs completed their listings: GigCapital8 (GIWWU) raised $220 million and Lake Superior Acquisition (LKSPU) raised $100 million, focusing on energy, social media, and consumer goods [4]. - Five SPACs filed for IPOs, including Xsolla SPAC 1 (XSOLU.RC) and Alussa Energy Acquisition II (ALUBU), both aiming to raise $250 million [8][10]. Group 3: Upcoming IPOs and Market Trends - 13 companies filed for IPOs, including BillionToOne (BLLN), Evommune (EVMN), and Central Bancompany (CBC), each planning to raise $100 million [6]. - The SEC issued new guidelines allowing companies to announce pricing ranges and set final pricing above the range, which may encourage more companies to proceed with listings amid the government shutdown [12].